Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced

“We are very pleased with the preliminary data showing 43% objective response rate in patients with non-CNS MET fusion solid tumors. The results in this specific cohort of patients adds to the accumulating evidence supporting the potential of vebreltinib as a highly selective and efficacious treatment against multiple tumor types harboring MET alterations. Alongside the Avistone data for vebreltinib in the treatment of gliblastoma with PTPRZ1 MET fusions, the clinical evidence for the efficacy of vebreltinib in MET fusions is very encouraging,” said Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics. “Based on the overall occurrence of these fusions in 0.1-0.3% of solid tumors, we believe the incidence is several thousand per year in the United States. Given the increasing patient access to next-generation sequencing, we expect it will become increasingly practical to identify and treat these patients with a targeted therapy such as vebreltinb. We look forward to providing additional clinical updates from the SPARTA Phase 2 trial as they become available.”